2. Academic Validation
  3. Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells

Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells

  • J Transl Med. 2024 May 13;22(1):450. doi: 10.1186/s12967-024-05269-6.
Francesca Cirillo 1,  Asia Spinelli 1,  Marianna Talia 1,  Domenica Scordamaglia 1,  Maria Francesca Santolla 1,  Fedora Grande 1,  Bruno Rizzuti 2 3,  Marcello Maggiolini 1,  Céline Gérard 4,  Rosamaria Lappano 5
Affiliations

Affiliations

  • 1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, 87036, Italy.
  • 2 Department of Physics, CNR-NANOTEC, SS Rende (CS), University of Calabria, Rende, CS, 87036, Italy.
  • 3 Institute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Zaragoza, 50018, Spain.
  • 4 Mithra Pharmaceutical, Rue Saint-Georges 5, Liège, 4000, Belgium. cgerard@mithra.com.
  • 5 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, 87036, Italy. rosamaria.lappano@unical.it.
PMID: 38741146 DOI: 10.1186/s12967-024-05269-6
Abstract

Background: Estetrol (E4) is a natural estrogen produced by the fetal liver during pregnancy. Due to its favorable safety profile, E4 was recently approved as estrogenic component of a new combined oral contraceptive. E4 is a selective ligand of Estrogen Receptor (ER)α and ERβ, but its binding to the G Protein-Coupled Estrogen Receptor (GPER) has not been described to date. Therefore, we aimed to explore E4 action in GPER-positive Triple-Negative Breast Cancer (TNBC) cells.

Methods: The potential interaction between E4 and GPER was investigated by molecular modeling and binding assays. The whole transcriptomic modulation triggered by E4 in TNBC cells via GPER was explored through high-throughput RNA Sequencing analyses. Gene and protein expression evaluations as well as migration and invasion assays allowed us to explore the involvement of the GPER-mediated induction of the plasminogen activator inhibitor type 2 (SERPINB2) in the biological responses triggered by E4 in TNBC cells. Furthermore, bioinformatics analysis was aimed at recognizing the biological significance of SERPINB2 in ER-negative breast Cancer patients.

Results: After the molecular characterization of the E4 binding capacity to GPER, RNA-seq analysis revealed that the plasminogen activator inhibitor type 2 (SERPINB2) is one of the most up-regulated genes by E4 in a GPER-dependent manner. Worthy, we demonstrated that the GPER-mediated increase of SERPINB2 is engaged in the anti-migratory and anti-invasive effects elicited by E4 in TNBC cells. In accordance with these findings, a correlation between SERPINB2 levels and a good clinical outcome was found in ER-negative breast Cancer patients.

Conclusions: Overall, our results provide new insights into the mechanisms through which E4 can halt migratory and invasive features of TNBC cells.

Keywords

Estetrol (E4); G protein-coupled estrogen receptor (GPER); SERPINB2; Triple-negative breast cancer (TNBC).

Figures
Products